acute myeloid leukemia (AML)

How your health care team can become your partner

Senior Director of Health Professional Programs, Alice Houk, describes how your health care team can become your Partner toward health in this interview.

Leigh Clark, Patient Educator, shares her insight into the bone marrow failure disease journey

This is the first episode of our new podcast. Leigh Clark, Patient Educator, describes the

(Auto-)immune signature in aplastic anemia.

Author(s):

Risitano AM

Primary Author:

Risitano AM

Journal Title:

Haematologica

Original Publication Date:

May 2018

Free text;

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927975/

Bone Marrow Disease(s):

acute myeloid leukemia (AML)

Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Achieved Outcomes Comparable With Matched Unrelated Donor Transplantation in Young Acquired Severe Aplastic Anemia

Author(s):

Lu Y, Sun RJ, Zhao YL, Xiong M, Cao XY, Zhang JP, Wei ZJ, Zhou JR, Liu DY, Lu DP

Primary Author:

Lu Y

Journal Title:

Biol Blood Marrow Transplant

Original Publication Date:

May 2018

Salvage haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is considered in patients with severe

Bone Marrow Disease(s):

acute myeloid leukemia (AML)

Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome

Author(s):

Slade M, DiPersio J, Westervelt P, Vij R, Schroeder M, Romee R

Primary Author:

Slade M

Journal Title:

Biology of Blood and Marrow Transplantation

Original Publication Date:

Nov 2017

Many hematologic malignancies are diseases of aging, and the use of hematopoietic cell transplant (HCT) is growing rapidly among older adults. Modern post-transplant

Bone Marrow Disease(s):

Orlando

Thank you for attending the 2017 Patient and Family Conference in Orlando, FL.

Event Date:

Sat, 11/04/2017 - 8:00am (EDT)

Conference Materials:

Intro to Bone Marrow Transplant

PNH

Aplastic Anemia

Personalized Medicine

MDS Understanding Your Diagnosis

Bone Marrow Disease(s):

Conference Event Type:

Patient and Family - Regional One Day

Kansas City

Thank you for attending the 2017 Patient and Family Conference in Kansas City, MO.

Event Date:

Sat, 10/14/2017 - 7:30am (EDT)

Register Here.

Conference Materials:

Aplastic Anemia

MDS and Myeloid Neoplasms

PNH

Bone Marrow Disease(s):

Conference Event Type:

Patient and Family - Regional One Day

Newark

Thank you for attending the 2017 Patient and Family Conference in Newark, NJ.

Event Date:

Sat, 09/16/2017 - 8:00am (EDT)

2017 Patient and Family Conference Newark

Conference Materials:

Personalized Medicine: Genetic Testing and the Implications for Future Therapies

Myelodysplastic Syndromes: Understanding Your Diagnosis and Current and Emerging Treaments

What You Need to Know About Aplastic Anemia

Understanding Bone Marrow Transplantation: Where Are We Now and What’s Coming?

PNH Understanding Your Diagnosis and Treatment

Bone Marrow Disease(s):

Conference Event Type:

Patient and Family - Regional One Day

Minneapolis

Thank you for attending the 2017 Minneapolis Patient and Family Conference.

Event Date:

Sat, 07/22/2017 - 8:00am (EDT)

Conference Materials:

Understanding Bone Marrow Transplants

PNH Managment

Aplastic Anemia: Understanding your Diagnosis and Treatment Options

Personalized Medicine: Genetic Testing and the Implications for Future Therapies

MDS: Understanding your Diagnosis and Current and Emerging Treatments

Bone Marrow Disease(s):

Conference Event Type:

Patient and Family - Regional One Day

Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia

Author(s):

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi, Gail J. Roboz, Jessica K. Altman, Richard M. Stone, Daniel J. DeAngelo, Ross L. Levine, Ian W. Flinn, Hagop M. Kantarjian, Robert Collins, Manish R. Patel, Arthur E. Frankel, Anthony S

Primary Author:

Eytan M. Stein

Journal Title:

Blood

Original Publication Date:

May 2017

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ~12% of patients with

Bone Marrow Disease(s):